^
    3d
    A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Genentech, Inc. | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    divarasib (RG6330) • rifampicin
    8d
    CLEANEST: MRSA Decolonization in Complicated Carriage (clinicaltrials.gov)
    P=N/A, N=211, Recruiting, Leiden University Medical Center | Trial completion date: Apr 2024 --> May 2028 | Trial primary completion date: Apr 2024 --> May 2028
    Trial completion date • Trial primary completion date
    |
    rifampicin
    9d
    PRISM-TB: Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (clinicaltrials.gov)
    P3, N=690, Not yet recruiting, University of California, San Francisco | Trial completion date: Nov 2029 --> Jun 2031 | Initiation date: Jan 2025 --> Oct 2026 | Trial primary completion date: Jun 2029 --> Dec 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    rifampicin
    16d
    Rifampicin Repurposing Reveals Anti-Melanogenic Activity in B16F10 Melanoma Cells. (PubMed, Molecules)
    These findings demonstrate that rifampicin inhibits melanogenesis through multiple signaling pathways, including PKA, MAPKs, and GSK-3β/β-catenin. This study highlights the potential of rifampicin to be repurposed as a topical agent for managing hyperpigmentation disorders, offering valuable insights into novel therapeutic strategies for pigmentation-related conditions.
    Journal
    |
    MITF (Melanocyte Inducing Transcription Factor)
    |
    rifampicin
    21d
    EBA, Safety and Tolerability of Sanfetrinem Cilexetil (clinicaltrials.gov)
    P2, N=54, Completed, TASK Applied Science | Recruiting --> Completed | N=105 --> 54 | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Sep 2023 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    rifampicin
    22d
    COPAT: Comparing Oral Versus Parenteral Antimicrobial Therapy (clinicaltrials.gov)
    P4, N=90, Terminated, West Virginia University | N=135 --> 90 | Trial completion date: Aug 2024 --> Feb 2025 | Enrolling by invitation --> Terminated | Trial primary completion date: Aug 2024 --> Feb 2025; DSMB recommendation based on safety benefit in Experimental (oral) arm
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    rifampicin
    23d
    A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Genentech, Inc.
    New P1 trial
    |
    divarasib (RG6330) • rifampicin
    30d
    WX081-DDI: Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Shanghai Jiatan Pharmatech Co., Ltd | Initiation date: Dec 2024 --> May 2025 | Trial primary completion date: Feb 2025 --> Oct 2025
    Trial initiation date • Trial primary completion date
    |
    itraconazole • rifampicin
    30d
    Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement (clinicaltrials.gov)
    P3, N=100, Suspended, Rush University Medical Center | Trial completion date: Dec 2025 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial suspension • Trial primary completion date • Head-to-Head
    |
    rifampicin
    1m
    Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride (clinicaltrials.gov)
    P1, N=68, Completed, Ahon Pharmaceutical Co., Ltd.
    New P1 trial
    |
    midazolam hydrochloride • omeprazole • rifampicin
    1m
    A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Feb 2025 --> Jun 2025
    Trial completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828) • itraconazole • rifampicin
    2ms
    Non-Tuberculous Mycobacterial Infection in AIDS Patients: A Detailed Description of 4 Cases, Including Histopathological Finding. (PubMed, Rev Med Chil)
    NTM infections in patients with AIDS generate a prolonged morbidity, frequent readmissions, require an extended combination treatment that may present interactions with ART, and are associated with different complications, including calcium and phosphorus disorders. Its diagnosis is complex in the absence of special blood cultures, requiring a microbiological study in multiple samples and with different techniques, including the support of histopathology.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    rifampicin
    2ms
    Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours (clinicaltrials.gov)
    P1, N=64, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    Recentin (cediranib) • rifampicin
    2ms
    Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis: BDLL Chinese Cohort (ChiCTR2400091867)
    P4, N=120, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New P4 trial
    |
    rifampicin
    2ms
    Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects (clinicaltrials.gov)
    P1, N=48, Completed, TYK Medicines, Inc | Recruiting --> Completed | Trial completion date: Aug 2024 --> Dec 2024
    Trial completion • Trial completion date
    |
    itraconazole • Kardorisso (asandeutertinib) • rifampicin
    2ms
    Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects (clinicaltrials.gov)
    P1, N=48, Completed, TYK Medicines, Inc | Recruiting --> Completed | Trial completion date: Aug 2024 --> Dec 2024
    Trial completion • Trial completion date
    |
    itraconazole • Kardorisso (asandeutertinib) • rifampicin
    3ms
    ToxZid: Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis (clinicaltrials.gov)
    P=N/A, N=280, Not yet recruiting, Albert Einstein College of Medicine | Trial completion date: Nov 2028 --> Sep 2029 | Initiation date: Nov 2024 --> Sep 2025 | Trial primary completion date: May 2028 --> Mar 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    rifampicin
    3ms
    A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=56, Completed, Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting --> Completed
    Trial completion
    |
    itraconazole • VC004 • rifampicin
    3ms
    Therapeutic drug monitoring of docetaxel administered for breast cancer in a patient receiving rifampicin and clarithromycin to treat nontuberculous mycobacteriosis: A case report. (PubMed, Mol Clin Oncol)
    The patient was diagnosed as having stage IV HER2-positive breast cancer, which was treated with a regimen of trastuzumab (8 mg/kg), pertuzumab (first dose: 840 mg; second dose onward: 420 mg) and docetaxel (75 mg/m2) every 3 weeks. After 4 months of chemotherapy, the patient received complete remission. In conclusion, concomitant use of rifampicin and clarithromycin may increase the blood concentration of docetaxel.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • rifampicin
    3ms
    Ferroptosis and Intrinsic Drug-induced Liver Injury by Acetaminophen and Other Drugs: A Critical Evaluation and Historical Perspective. (PubMed, J Clin Transl Hepatol)
    More recently, ferroptosis-a novel, non-apoptotic form of cell death-was identified in NRAS-mutant HT-1080 fibrosarcoma cells exposed to erastin and other NRLs...Overall, the published data support the idea that multi-layered endogenous antioxidant defense mechanisms in the liver limit the occurrence of pathophysiologically relevant LPO under normal conditions. Only when these defense mechanisms are severely compromised does ferroptosis become a significant mode of drug-induced cell death.
    Review • Journal
    |
    GPX4 (Glutathione Peroxidase 4)
    |
    NRAS mutation
    |
    methotrexate • erastin • rifampicin
    3ms
    Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant (clinicaltrials.gov)
    P1, N=42, Completed, Bellus Health Inc. - a GSK company | N=32 --> 42
    Enrollment change
    |
    rifampicin
    4ms
    Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug Interactions. (PubMed, Clin Pharmacol Ther)
    The PBPK model well-described the single and multiple-dose adagrasib PK data as well as DDI data with itraconazole, rifampin, midazolam, warfarin, dextromethorphan, and digoxin, with model predictions within 1.5-fold of the observed clinical data. is predicted to be a strong inhibitor of CYP3A4, a moderate inhibitor of CYP2C9 and CYP2D6, and an inhibitor of P-glycoprotein (P-gp). These results successfully supported regulatory interactions with the United States Food and Drug Administration regarding dosing recommendations for when adagrasib is used concomitantly with other medications, supporting a range of label claims in lieu of clinical trials.
    PK/PD data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • itraconazole • midazolam hydrochloride • rifampicin
    4ms
    WX081-DDI: Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Shanghai Jiatan Pharmatech Co., Ltd
    New P1 trial
    |
    itraconazole • rifampicin
    4ms
    WISH: A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients (clinicaltrials.gov)
    P3, N=450, Recruiting, Shanghai Jiatan Pharmatech Co., Ltd | Enrolling by invitation --> Recruiting | Trial completion date: Mar 2025 --> Oct 2026 | Trial primary completion date: Jan 2025 --> Dec 2025
    Enrollment status • Trial completion date • Trial primary completion date
    |
    rifampicin
    4ms
    An Adaptive Trial to Find the Safest and Shortest TB Preventive Regimens. (clinicaltrials.gov)
    P2/3, N=1800, Not yet recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre | Initiation date: Oct 2024 --> Feb 2025
    Trial initiation date
    |
    rifampicin
    4ms
    Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects. (PubMed, Clin Transl Sci)
    Based on the preclinical characterization of SKLB1028 metabolism, three drug-drug interaction clinical studies were performed to investigate the effects of itraconazole, rifampin (CYP3A4 inhibitor and inducer, respectively), and gemfibrozil (CYP2C8 inhibitor) on the metabolism of SKLB1028. Co-administration with rifampin reduced the AUC of SKLB1028 by ~30%, while the Cmax did not change significantly. All treatments were well tolerated in all three studies.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation
    |
    itraconazole • rifampicin • ruserontinib (SKLB-1028)
    4ms
    P-RIF: Precision Rifampin Trial for Personalized Dosing (clinicaltrials.gov)
    P1, N=200, Not yet recruiting, University of Virginia | Phase classification: P1/2 --> P1 | Initiation date: Jul 2024 --> Jan 2025
    Phase classification • Trial initiation date
    |
    rifampicin
    4ms
    A Single-center, Open-label, Fixed-sequence, Drug-Drug Interaction Study of BPI-16350 co-administered with Rifampin or Itraconazole in Healthy Volunteers (ChiCTR2400090190)
    P1, N=36, Completed, Beijing Friendship Hospital ,Capital Medical University; Beijing Friendship Hospital ,Capital Medical University
    New P1 trial
    |
    itraconazole • tibremciclib (BPI-16350) • rifampicin
    4ms
    Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis (clinicaltrials.gov)
    P2, N=75, Active, not recruiting, Thirty Respiratory Limited | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Apr 2025
    Enrollment closed • Trial primary completion date
    |
    rifampicin
    4ms
    A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Aug 2025 --> Feb 2025
    Trial completion date • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828) • itraconazole • rifampicin
    5ms
    Abnormally high plasma concentrations of M-4, the active metabolite of edoxaban, at the onset of acute kidney injury in a patient receiving rifampin and clarithromycin: a case report. (PubMed, J Pharm Health Care Sci)
    This case suggests that in patients with impaired renal function taking edoxaban, co-administration of carboxylesterase-1 inducers such as rifampin and/or OATP1B1 inhibitors such as rifampin or clarithromycin may increase plasma concentrations of M-4 to clinically non-negligible levels.
    Journal
    |
    CES1 (Carboxylesterase 1)
    |
    rifampicin
    5ms
    Drug-Drug Interaction (DDI) Study for TQB3616 (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial
    |
    culmerciclib (TQB3616) • itraconazole • rifampicin
    5ms
    Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Jemincare
    New P1 trial
    |
    itraconazole • rifampicin
    5ms
    INSPIRE-BDLL: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort (clinicaltrials.gov)
    P3, N=120, Not yet recruiting, Huashan Hospital
    New P3 trial
    |
    rifampicin
    5ms
    VA INTREPID: Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics (clinicaltrials.gov)
    P4, N=880, Recruiting, VA Office of Research and Development | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    rifampicin
    5ms
    Early prediction and impact assessment of CYP3A4-related drug-drug interactions for small molecule anti-cancer drugs using human-CYP3A4-transgenic mouse models. (PubMed, Drug Metab Dispos)
    Victim drugs brigatinib and lorlatinib were evaluated with the new approach in combination with the perpetrator drugs itraconazole and rifampicin. The model was able to adequately describe the inhibition of CYP3A4 metabolism and the subsequent magnitude of change in exposure. However, it was unable to accurately predict the magnitude of change in exposure of victim drugs in combination with an inducer.
    Preclinical • Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Lorbrena (lorlatinib) • Alunbrig (brigatinib) • itraconazole • rifampicin
    5ms
    A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, Jiangsu vcare pharmaceutical technology co., LTD
    New P1 trial
    |
    itraconazole • VC004 • rifampicin
    6ms
    A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants (clinicaltrials.gov)
    P1, N=35, Completed, Celgene | Recruiting --> Completed
    Trial completion
    |
    itraconazole • golcadomide (CC-99282) • rifampicin
    6ms
    ASTERoiD: Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI (clinicaltrials.gov)
    P2/3, N=3400, Recruiting, Centers for Disease Control and Prevention | Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2028 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    rifampicin
    6ms
    ToxZid: Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis (clinicaltrials.gov)
    P=N/A, N=280, Not yet recruiting, Albert Einstein College of Medicine
    New trial
    |
    rifampicin
    6ms
    Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers. (PubMed, Clin Transl Sci)
    Coadministration with rifampin decreased these same variables by 61.27%, 74.21%, and 75.19%, respectively. These results confirm that olverembatinib is primarily metabolized by CYP3A4 in humans, suggesting that caution should be exercised with concurrent use of olverembatinib and strong CYP3A4 inhibitors or inducers.
    PK/PD data • Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    ABL1 T315I
    |
    Nailike (olverembatinib) • itraconazole • rifampicin
    7ms
    Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care (clinicaltrials.gov)
    P3, N=402, Completed, Wits Health Consortium (Pty) Ltd | Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    rifampicin